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Abstract
Purpose Based on recovered metabolite ratios in urine, it has
been concluded that paracetamol glucuronidation may be up-
regulated upon multiple dosing. This study investigates para-
cetamol clearance in neonates and infants after single and
multiple dosing using a population modelling approach.
Methods A population pharmacokinetic model was devel-
oped in NONMEMVI, based on paracetamol plasma concen-
trations from 54 preterm and term neonates and infants, and on
paracetamol, paracetamol-glucuronide and paracetamol-
sulphate amounts in urine from 22 of these patients. Patients
received either a single intravenous propacetamol dose or up
to 12 repeated doses.
Results Paracetamol and metabolite disposition was best de-
scribed with one-compartment models. The formation
clearance of paracetamol-sulphate was 1.46 mL/min/kg1.4,
which was about 5.5 times higher than the formation clearance
of the glucuronide of 0.266 mL/min/kg. The renal excretion
rate constants of both metabolites was estimated to be 11.4
times higher than the excretion rate constant of unchanged
paracetamol, yielding values of 0.580 mL/min/kg.
Developmental changes were best described by bodyweight
in linear relationships on the distribution volumes, the forma-
tion of paracetamol-glucuronide and the unchanged excretion
of paracetamol, and in an exponential relationship on the for-
mation of paracetamol-sulphate. There was no evidence for
up-regulation or other time-varying changes in any of the
model parameters. Simulations with this model illustrate
how paracetamol-glucuronide recovery in urine increases over
time due to the slower formation of this metabolite and in the
absence of up-regulation.
Conclusions Developmental changes, described by
bodyweight-based functions, rather than up-regulation, ex-
plain developmental changes in paracetamol disposition in
neonates and infants.
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Introduction
Paracetamol (acetaminophen) is a commonly prescribed drug
to treat moderate pain or fever in adults and children, includ-
ing neonates. Paracetamol was also shown to reducemorphine
requirements in post-operative neonates and infants [1],
and an association between paracetamol exposure and
closure of a patent ductus arteriosus in neonates has
also been suggested [2–4].
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In adults, the main elimination pathway for paracetamol is
glucuronidation. Since the glucuronidation capacity is greatly
reduced in neonates, the elimination of paracetamol is directed
towards sulphation and unchanged renal excretion in these
patients [5]. Different developmental patterns for the various
clearance pathways of paracetamol result in continuous
changes in the relative contribution of each pathway to the
overall paracetamol clearance as well as in changes in total
paracetamol clearance. Although these changes are generally
thought to be the main cause of age-dependent differences of
drug dose requirements in children [5], the influence of devel-
opmental changes on the pharmacokinetics of paracetamol
and its metabolites have not been determined. Moreover, there
have been reports of the glucuronidation of paracetamol being
up-regulated upon multiple dosing in adults [6] as well as in
neonates and infants [7, 8]. These studies were all based on
recovered paracetamol andmetabolite ratios in urine, but these
results have never been confirmed in a population analysis.
One of the advantages of a population analysis is that elimi-
nation pathways and the demographic and clinical factors af-
fecting them can be studied separately [9].
The current study investigates to what extent paracetamol
is cleared through glucuronidation, sulphation or unchanged
renal excretion upon single and multiple dosing in neonates
and infants, using paracetamol plasma concentrations and re-
covered paracetamol and metabolite amounts in urine. This is
done by firstly quantifying the influence of developmental
changes on the pharmacokinetics of paracetamol after intrave-
nous administration of propacetamol, which is the precursor
of paracetamol, and subsequently investigating potential time-
related trends in paracetamol glucuronidation.
Methods
The current analysis was performed based on pooled data of
plasma paracetamol concentrations and recovered paraceta-
mol andmetabolite amounts in urine of earlier reported studies
on intravenous propacetamol disposition in preterm and term
neonates and infants [7, 10, 11]. Details on patient character-
istics, inclusion criteria and sampling are available in the orig-
inal references. Study protocols were approved by the local
ethics board of the University Hospital Leuven, and patients
were included after written informed consent was obtained
from the parents or legal guardians of patients included in
the study.
Plasma paracetamol pharmacokinetic studies
Neonates exposed to either single or repeated intravenous ad-
ministration of propacetamol were included.
In the single-dose study, neonates received one dose of 20
or 40 mg/kg of propacetamol (paracetamol equivalent 10 or
20 mg/kg) on the first day of postnatal life, and plasma sam-
ples were collected up to 10 h afterwards. Propacetamol was
administered when neonates underwent minor painful proce-
dures or as additional treatment in neonates on opioid treat-
ment. Paracetamol plasma concentrations were determined
using fluorescence polarisation immunoassay (Adx, Abbott
Laboratories, North Chicago, IL). Lower limit of quantifica-
tion was 1 mg/L, and precision was 7 % [10].
In the repeated dose study, a loading dose of 30 mg/kg
propacetamol was administered, followed by at least 1, and
up to 11 (median = 5) maintenance doses of 20 mg/kg (para-
cetamol equivalent 15 and 10 mg/kg, respectively), using a
postmenstrual age (PMA) dependent dosing interval of q6h to
q12h. Inclusion criteria were similar to the single-dose study,
but the age of the patients was not limited to the first day of
postnatal life. Paracetamol plasma concentrations were mea-
sured using high-performance liquid chromatography (HPLC)
as described earlier [11]. The lower limit of quantification was
0.08 mg/L, and variation coefficients of intra- and inter-day
accuracy and precision were all below 15 %.
In these studies, metabolite concentrations were not
analysed in plasma.
Urine paracetamol metabolite study
Urine collections were performed in neonates exposed to re-
peated dose administration of propacetamol. Collection was
started at initiation of the loading dose, and all urine was
collected in 6, 8, or 12 h aliquots, related to the PMA-
dependent dosing interval. At the end of every collection time
interval, total urine volume was recorded and a representative
urine sample was stored until analysis. Urine collection was
stopped when the latest collection period was incomplete. At
best, urine collection was stopped one time interval after the
last administration. Paracetamol-glucuronide, paracetamol-
sulphate and unchanged paracetamol urine concentrations
were determined using HPLC methodology as described ear-
lier [7]. The lower limit of quantification was 1 μg/L.
Variation coefficients in intra- and inter-day accuracy and pre-
cision were all below 15 %.
Pharmacokinetic analysis
A population pharmacokinetic model was developed using
NONMEM VI (Globomax LLC, Hanover, MD, USA) with
PLT Tools [12] for visualization of the data. The first-order
estimation algorithm with interaction (FOCE-I) was used.
Propacetamol doses and the recovered metabolite amounts
in urine were expressed as paracetamol equivalents.
Model development was performed in four steps: (1)
choice of the structural model, (2) choice of the error model,
(3) covariate analysis and (4) evaluation of the model. For the
inclusion of fixed and random model parameters as well as
Eur J Clin Pharmacol
covariates, a decrease in objective function corresponding to
p<0.01 was considered to be statistically significant assuming
a χ2 distribution. In addition, the following goodness-of-fit
plots were used for diagnostic purposes: (1) observed versus
population predictions, (2) observed versus individual predic-
tions, (3) conditional weighted residuals versus time and (4)
conditional weighted residuals versus population predictions.
For the structural model, one and two compartments were
explored to describe the time-course of the paracetamol plas-
ma concentrations. Since the metabolite concentrations in
plasma were not measured, assumptions for the structural
model were necessary, for which the same approach was
followed as previously reported population model for paracet-
amol [13]. Briefly, the distribution volumes of both metabo-
lites were set to 18 % of the volume of the parent compound,
based on reported values in adults [14]. Based on physiolog-
ical plausibility, the same excretion rate constant (k) was as-
sumed for bothmetabolites, and this value was estimated to be
a multiple of the excretion rate constant of the parent com-
pound. Different values were estimated for the formation rate
constants of the metabolites.
Inter-individual variability in the model parameters was
tested assuming log-normal distribution using Eq. 1:
Pi ¼ Pp *exp ηið Þ ð1Þ
in which Pi is the individual parameter estimate for the ith
individual, Pp represents the population parameter value (also
known as typical parameter value) for parameter P, and ηi is a
random variable for the ith individual from a normal distribu-
tion with a mean of zero and an estimated variance. Residual
unexplained variability in the observed drug and metabolite
concentrations proportional, additive and a combination error
model were tested.
A systematic covariate analysis was performed to identify
the best descriptor of the developmental changes in the phar-
macokinetics of paracetamol and its metabolites. The covari-
ates bodyweight, postnatal age (PNA) and PMAwere tested in
linear and exponential equations:
Pi ¼ Pp * covð Þn ð2Þ
in which Pi and Pp represent the individual and population
parameter values respectively and cov represents the value
of the covariate for the ith individual. n is the exponent that
is fixed to 1 in linear equations and estimated in exponential
equations. Additionally, sex, preterm birth and the clinical trial
that data were obtained from were tested as categorical covar-
iates, estimating parameter values for one subpopulation as a
fraction of the other.
All covariates were added to the base model separately, and
considered statistically significant if the objective function
decreased 6.63 points or more (p<0.01). When more than
one significant covariate was found for the base model, the
covariate-adjusted model with the largest decrease in objec-
tive function was chosen as the basis to explore the influence
of additional covariates with the use of the same criteria.
Afterwards, a backwards deletion procedure was performed
on the full model, in which the included covariates were ex-
cluded one at a time and only retained if the increase in ob-
jective function was more than 7.88 points (corresponding to
p<0.005).
The presence of time-related changes in the formation of
paracetamol-glucuronide (i.e. up-regulation) was further in-
vestigated by either estimating the formation clearance of the
paracetamol-glucuronide for later doses within an individual
as a multiple of the formation clearance of the first dose, or by
estimating continuous linear or exponential changes in the
glucuronidation clearance over time. The criteria used for
the covariate model building were also used to determine
whether inclusion of time-related changes for paracetamol
glucuronidation in the model significantly improved the mod-
el fit to the data.
Model evaluation
Identifiability of model parameters and model stability were
investigated using the condition number and a bootstrap pro-
cedure. To obtain the condition number, the highest eigenval-
ue in the NONMEM output of the final model fit was divided
by the lowest eigenvalue. In the bootstrap procedure, 100
replicates of the original data were generated by resampling
with replacement, and these datasets were fit to the final
model.
In addition, goodness-of-fit plots were generated, including
plots of both individual predicted and population predicted
concentrations (in plasma) or amounts (in urine) versus ob-
served concentrations or amounts. Individual predictions are
the result of a model fit to the data, which is based on dosing
history, sampling time, individual covariate information and
observed concentrations. Population predictions on the other
hand are based on the population parameter values, the dosing
history, sampling times and individual covariate information
alone. Plots of conditional weighted residuals versus time and
versus population predicted concentrations were also generat-
ed, and special attention was paid to the former to investigate
potential time-trends.
Finally, normalized prediction distribution errors (NPDE)
[15] were used as a simulation-based diagnostic to assess mod-
el performance. For this, the dataset was simulated 500 times.
The NPDE package in R was subsequently used to calculate
the NPDE for each observation, by comparing the observed
concentrations and amounts to the simulated reference distri-
bution. Special attention was again paid to the plot of NPDE’s
versus time, to further establish whether there were any time-
related trends in the observed paracetamol concentrations or
recovered paracetamol and metabolite amounts in urine.
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Simulations
To determine the recovery pattern of paracetamol and its me-
tabolites in urine over time, model simulations were per-
formed with the final model and a ‘typical individual’, which
is defined as a hypothetical individual with population values
(i.e. typical values) for all model parameters. The bodyweight
of this ‘typical individual’ was selected to be 2.5 kg, which is
the mean bodyweight in the dataset. In the simulation, a para-
cetamol equivalent dose of 15 mg/kg was administered intra-
venously during a 15-min infusion, analogue to the studies
fromwhich the data analysed in the current study were obtain-
ed. The simulated relative cumulative amount of paracetamol,
paracetamol-glucuronide and paracetamol-sulphate recovered
in urine within the first 36 h was determined. Additionally, the
amount of paracetamol, paracetamol-glucuronide and
paracetamol-sulphate recovered within each 6-h urine collec-
tion interval was determined.
Results
This analysis was based on data from 54 patients, who at the
start of the study had a median bodyweight of 2.5 kg (range,
0.5–6.3 kg), a median PNA of 1 day (range, 1–140 days) and a
median PMA of 36 weeks (range, 27–60 weeks). A total of
353 observed paracetamol plasma concentrations were avail-
able for analysis and 435 observations of the amounts of the
parent compound or the metabolites in urine samples. The
median number of propacetamol doses per patient was 1
(range, 1–12).
Figure 1 depicts a schematic representation of the pharma-
cokinetic model for paracetamol and its metabolites, as well as
the equations used to describe the parameters in the model.
Inter-individual variability was identified for the distribu-
tion volume of paracetamol, for the formation clearances of
the metabolites and for the unchanged renal clearance of para-
cetamol. For the intra-individual variability and residual error,
a combination model was most suitable for the paracetamol
concentrations in plasma, while additive errors were best for
the recovered amounts of parent compound and metabolites in
urine.
Bodyweight in a linear equation was found to be the most
predictive covariate for the distribution volume of paraceta-
mol (V1) and as the distribution volumes of the metabolites
were a percentage of this distribution volume, the covariate
relationship perpetuated in these parameters as well.
Additionally, bodyweight was found to be the most predictive
covariate for the formation of paracetamol-glucuronide (CL1)
and the unchanged excretion of paracetamol (CL4) in a linear
relationship, with the latter was also being perpetuated to the
excretion clearance of the metabolites (CL3 and CL5). For the
formation of paracetamol-sulphate (CL2), the most predictive
covariate relationship was bodyweight in an exponential equa-
tion with an estimated exponent of 1.40 (relative standard
error, 9.3 %).
After inclusion of the bodyweight-based covariate relation-
ships, no other statistically significant covariates related to
either patient characteristics or clinical trial characteristics
could be identified. Diagnostics of this model did not suggest
time-related model misspecification. Additionally, when
estimating the value for glucuronidation clearance (CL1)
for the later doses as a multiple of the glucuronidation
clearance value for the first dose, the estimated value of
this fraction was 1.04, which did not statistically signif-
icantly improve the model fit. Including continuous
time-related changes on this parameter in a linear or
exponential relationships yielded estimates of respective-
ly the slope and exponent that approached 0 and no
statistically significant improvement of the model fit.
All these results indicate that the glucuronidation clear-
ance (CL1) at earlier and later time points remain essen-
tially the same.
Table 1 shows the parameter values obtained in the final
model fit as well as the mean parameter values obtained in the
bootstrap procedure. The coefficients of variations for the
structural parameters are all below 30 % in both the original
model fit as well as in the bootstrap procedure. This indicates
that these parameters could be estimated with good precision
from the data. The fact that all mean parameter values in the
bootstrap procedure are within 10 % of the values obtained in
the original model fit indicates that the model is robust. The
condition number of this model was 38, with a condition
number lower than 1000 indicating a model to be sufficiently
supported by the data.
The plot of conditional weighted residuals versus time pre-
sented in Fig. 2 confirms that there is no time-related model
misspecification of paracetamol plasma concentrations, or of
the recovered paracetamol and metabolite amounts in urine.
The plots of individual prediction versus observed values in
supplemental Fig. S1A show no bias and neither do plots of
conditional weighted residuals versus the predicted concentra-
tion in supplemental Fig. S1C. Both plots suggest that
throughout the study, paracetamol concentrations in
plasma as well as paracetamol and metabolite amounts
in urine can be accurately described by a pharmacoki-
netic model that does not include time-varying elements
in the glucuronidation clearance of paracetamol (CL1) or
any other model parameter.
The plots of the population predictions versus observed
concentrations in supplemental Fig. S1B show small trends,
especially for the metabolites. This suggests that although
description of the data with this model is accurate (supplemen-
tal Fig. S1A), caution is warranted in using this model for
predictions outside the studied patient population or in basing
dosing algorithms on this model.
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The NPDE analysis showed that the final model can accu-
rately predict paracetamol concentrations in plasma and para-
cetamol and metabolite amounts in urine for this dataset.
Supplemental Fig. 2 show the distribution of NPDE’s in time.
These unbiased plots further confirm our finding that in this
young population, paracetamol elimination can be described
by a model without time-varying aspects in any of the studied
clearance routes. Expected means and variance values for the
NPDE distribution of accurate models are 0 and 1, respective-
ly. The values for the observed data deviated slightly from
these values with 0.128 and 1.03 respectively for paracetamol
in plasma, −0.128 and 0.870 for paracetamol in urine, 0.0777
and 1.10 for paracetamol-glucuronide in urine and 0.0925 and
0.822 for paracetamol-sulphate in urine.
Fig. 1 Schematic representation of the pharmacokinetic model for
paracetamol and two of its metabolites and the equations used for each
model parameter. V distribution volume of the designated compartment,
CL clearance of the designated pathway, P paracetamol, PG paracetamol-
glucuronide, PS paracetamol-sulphate, Pp population parameter value of
the designated parameter, BW bodyweight, η random variable from a
normal distribution with a mean of 0 and estimated variance, n
exponent, k elimination rate constant of the designated elimination
route, mf multiplication factor
Table 1 Obtained
pharmacokinetic model
parameters including the relative
standard error (RSE) of the
original model fit and of the
bootstrap
Parameter (unit) Model fit (RSE%) Bootstrap (RSE%)
Fixed effects
V1 (L/kg) 1.06 (4.34) 1.05 (4.47)
V2=V3 (L/kg) 0.191 (derived parameter) 0.190 (derived parameter)
CL1 (mL/min/kg) 0.266 (17.4) 0.273 (18.7)
CL2 (mL/min/kg
n) 1.46 (14.8) 1.45 (15.9)
CL4 (mL/min/kg) 0.285 (6.98) 0.282 (7.99)
n 1.40 (9.29) 1.41 (9.52)
mf 11.3 (21.5) 11.3 (23.3)
CL3=CL5 (mL/min/kg) 0.580 (derived parameter) 0.577 (derived parameter)
Inter-individual variability (variance)
V1 0.0925 (29.5) 0.0889 (32.7)
CL1 0.599 (41.6) 0.561 (44.7)
CL2 0.312 (33.3) 0.294 (32.7)
CL4 0.0879 (52.2) 0.0936 (74.2)
Residual variability (variance)
P plasma, additive (mg/L) 0.354 (29.4) 0.383 (42.7)
P plasma, proportional 0.0198 (16.5) 0.0188 (30.7)
PG urine, additive (mg) 0.223 (14.5) 0.222 (18.6)
P urine , additive (mg) 0.188 (27.5) 0.183 (14.5)
PS urine, additive (mg) 0.332 (35.9) 0.341 (29.6)
See Fig. 1 for the explanation of the symbols
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The results of the simulation procedure with the final
model in Fig. 3 illustrate how the percentage of para-
cetamol and metabolites that is recovered in urine in
consecutive 6-h intervals changes over time. Although
all clearances in the model remain constant, the percent-
age of the recovered paracetamol-glucuronide increases
over time. This can be explained by the slower forma-
tion of the glucuronide compared to the sulphate, which
causes the recovery of glucuronide in urine to occur
later in time.
Discussion
In this study, a population pharmacokineticmodelwas developed
to describe the time-course of paracetamol and two of its com-
mon metabolites in preterm and term neonates and infants. In
order to investigate potential up-regulation of paracetamol
glucuronidation upon multiple dosing in these patients, the influ-
ence of developmental changes on the disposition of paracetamol
was first quantified. Subsequently, we investigated whether the
relative contributions of the various clearance pathways
Fig. 2 Conditional weighted residuals versus time for paracetamol concentrations in plasma, and for the recovered amounts of paracetamol-glucuronide,
unchanged paracetamol and paracetamol-sulphate in urine
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remained constant upon multiple dosing or whether there was
up-regulation of the glucuronidation pathway in particular. No
time-related factors other than changes in bodyweight reflecting
developmental changes could be identified to influence the elim-
ination of paracetamol upon single and multiple dosing. The
thorough model evaluation and validation procedures applied
to the pharmacokinetic model support the conclusions from this
study.
Developmental changes in drug clearance are thought to be
the leading cause of age-dependent differences in drug re-
quirements in the paediatric population [5]. According to this
model, paracetamol is mostly metabolized by sulphation in
neonates and infants, which is an efficient elimination path-
way at birth [5]. The exponential covariate relationship with
bodyweight that was found to describe the development of
this pathway in the current study population, suggests that this
pathway is developing rapidly. The current analysis shows the
glucuronidation capacity to increase with bodyweight as well,
although in this very young population, the increase in
glucuronidation capacity is still slower than the increase in
sulphation capacity. The increase in the renal excretion of
unchanged paracetamol and of the two paracetamol metabo-
lites is similar to the increase in glucuronidation capacity.
Most of this excretion occurs through glomerular filtration,
which is blood flow dependent.
Both renal excretion and drug glucuronidation are known
to reach full maturity well after the neonatal period [5]. As the
capacity of sulphotransferases is limited, the glucuronidation
pathway increases in importance throughout childhood, caus-
ing sulphation to be a relatively minor pathway for paraceta-
mol clearance in adults. Determining the full developmental
patterns for these three elimination pathways of paracetamol
throughout childhood was outside the scope of this study.
Studies by our own group and by others, in both adult and
paediatric populations have previously been interpreted to sug-
gest that the glucuronidation clearance of paracetamol is up-
regulated upon multiple dosing [6–8]. These studies, however,
relied on analysing the ratios of paracetamol and metabolites
recovered in urine over consecutive collection-intervals and
did not take paracetamol plasma concentrations into account.
We were able to obtain a comprehensive understanding of the
underlying metabolic and elimination processes of paraceta-
mol, by combining pharmacokinetic data from plasma and
urine in a population modelling approach. Figure 3 illustrates
that the expected ratio of paracetamol and the two metabolites
recovered over 6-h intervals in urine is indeed continuously
changing, despite the fact that all clearances remain constant
over time. As the formation of the glucuronide is considerably
slower than the formation of the sulphate metabolite, the glu-
curonide metabolite is recovered in urine later. Although in line
with previous observations that the fraction of recovered
paracetamol-glucuronide increases during the first days of
paracetamol treatment, the previous conclusion that this is
caused by up-regulation of the glucuronidation pathway
should be rejected. Therefore, even though data on complete
urine recovery can be used to investigate which fractions of
drugs are eliminated through various pathways, in our opinion,
methods based on recovered drug and metabolite ratios should
not be used to study time-varying changes in drug elimination
pathways, either in adults or in paediatrics. We recommend
confirming these findings with a population analysis instead.
The necessary assumption in the structural model regarding
pharmacokinetic parameters of the metabolites is not expected
to influence our conclusions on the developmental patterns of
elimination pathways or on the absence of up-regulation of the
glucuronidation pathway in particular. Our assumptions were
Fig. 3 Relative cumulative
amount of paracetamol-
glucuronide (green, G),
unchanged paracetamol (blue, P)
and paracetamol-sulphate
(purple, S) recovered in urine
after a single dose in a typical
individual with a bodyweight of
2.5 kg, with the recovered
metabolite amounts being
expressed in molar paracetamol
equivalents. Percentage
paracetamol and metabolites
recovered in each 6 h urine
collection interval are indicated at
the top of the graph
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based on literature findings [13, 14] and as all data points are
influenced similarly by these assumptions, they are not expected
to have introduced systematic trends or bias related to time after
start of treatment or related to developmental difference between
patients.
In conclusion, there is no evidence for up-regulation of
paracetamol glucuronidation in preterm and term neonates
and infants. The only increases in paracetamol glucuronidation
that could be identified in this population were resulting from
growth and developmental changes, and these were adequately
described by bodyweight-based covariate relationships.
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